Ardelyx Inc (ARDX)
NASDAQ:ARDX
Want to see ARDX full AI Analyst Report?
ARDX Stock Chart & Stats
$6.45
-$0.17(-3.14%)
At close: 4:00 PM EST
$6.45
-$0.17(-3.14%)
Day’s Range― - ―
52-Week Range$3.49 - $8.40
Previous CloseN/A
Volume1.36M
Average Volume (3M)3.87M
Market Cap
$1.36B
Enterprise Value$1.67B
Total Cash (Recent Filing)$238.07M
Total Debt (Recent Filing)$208.26M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Jul 30, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding247,029,390
10 Day Avg. Volume2,690,190
30 Day Avg. Volume3,872,320
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)8.42
Price to Sales (P/S)3.45
P/FCF Ratio-31.96
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit4.25
Enterprise Value/Ebitda-49.02
Forecast
1Y Price Target
$16.50Price Target Upside155.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$545.48M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth & High Gross MarginsArdelyx shows durable top-line momentum with expanding product revenues and very high gross margins (~85–93%). High product economics provide long-term gross-profit resilience as the company scales sales, improving the leverage of incremental revenue toward eventual operating cash‑flow conversion.
Ibsrela Commercial MomentumIbsrela is a clear growth engine with sustained high single‑digit to double‑digit adoption increases and reiterated multi‑year targets. Durable demand and management’s $1B by 2029 target underpin predictable revenue runway, supporting long‑term commercialization scale and investment payback assumptions.
Advancing Pipeline And Next‑gen ProgramProgressing Phase 3 trials and IND‑enabling work establishes a multi‑year R&D cadence that can expand indications and lifecycle value. Successful trials or label expansions would materially extend commercial exclusivity and diversify future revenue beyond current franchises, strengthening long‑run product portfolio resilience.
Bears Say
Rising Financial LeverageLeverage increasing above 1.0 alongside ongoing losses raises refinancing and solvency risk if operating cash flow does not turn positive. Higher debt amplifies mandatory interest/principal obligations, reducing financial flexibility for future R&D or commercial investments during adverse revenue scenarios.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business remains reliant on external capital (debt/equity) until operations become cash generative. This structural cash dependence increases dilution or leverage risk and constrains ability to self‑fund pipeline and commercialization growth over the medium term.
Elevated OpEx And Profitability PressureA sustained OpEx ramp for commercialization and Phase‑3 activity keeps the pathway to GAAP and cash profitability challenging. Even with revenue growth, high fixed operating costs can delay breakeven and increase capital needs if revenue or reimbursement dynamics underperform expectations.
Ardelyx News
ARDX FAQ
What was Ardelyx Inc’s price range in the past 12 months?
Ardelyx Inc lowest stock price was $3.49 and its highest was $8.40 in the past 12 months.
What is Ardelyx Inc’s market cap?
Ardelyx Inc’s market cap is $1.36B.
When is Ardelyx Inc’s upcoming earnings report date?
Ardelyx Inc’s upcoming earnings report date is Jul 30, 2026 which is in 56 days.
How were Ardelyx Inc’s earnings last quarter?
Ardelyx Inc released its earnings results on Apr 30, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.008.
Is Ardelyx Inc overvalued?
According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued.
Does Ardelyx Inc pay dividends?
Ardelyx Inc does not currently pay dividends.
What is Ardelyx Inc’s EPS estimate?
Ardelyx Inc’s EPS estimate is -0.04.
How many shares outstanding does Ardelyx Inc have?
Ardelyx Inc has 247,029,390 shares outstanding.
What happened to Ardelyx Inc’s price movement after its last earnings report?
Ardelyx Inc reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went up 8.689%.
Which hedge fund is a major shareholder of Ardelyx Inc?
Currently, no hedge funds are holding shares in ARDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ardelyx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.50 (155.81% Upside)
$16.50 (155.81% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $533.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.4%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.91%
12-Months-Change
Fundamentals
Return on Equity
-38.11%
Trailing 12-Months
Asset Growth
22.99%
Trailing 12-Months
Company Description
Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
ARDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong operational and commercial achievements — notably robust Ibsrela growth (58% YoY), solid product revenue expansion (+38% total product revenue), active pipeline advancement (EXCEL Phase 3 initiated with rapid site activation), improved net loss versus prior year, and strengthened financial optionality via debt refinancing and $238M in cash. Headwinds include elevated and growing OpEx tied to commercialization and Phase 3 activity, GAAP reporting complexity for Exposa due to prior‑year adjustments, Q1 seasonality and storm‑related disruptions, and near‑term gross‑to‑net pressure. On balance the company reiterated mid‑ and long‑term revenue targets and appears confident in execution, though profitability and competitive risk remain items to monitor.View all ARDX earnings summariesARDX Stock 12 Month Forecast
Average Price Target
$16.50
▲(155.81% Upside)
Technical Analysis
Vericel
―
Viridian Therapeutics
―
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Ownership Overview
3.66% Insiders
22.24% Mutual Funds
11.20% Other Institutional Investors
48.80% Public Companies and
Individual Investors